By Gilang Cahya 
A groundbreaking study conducted by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has unveiled a potentially significant underestimation of disease progression in many patients diagnosed with high-risk, nonmetastatic hormone-sensitive prostate cancer. The findings, published in the esteemed journal JAMA Network Open, suggest that nearly half of these patients, who were initially classified as having localized disease based on conventional imaging techniques, actually harbor metastatic cancer when assessed with advanced prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging. This revelation carries profound implications for how prostate cancer is staged, treated, and understood.
The Limitations of Conventional Imaging in Prostate Cancer Staging
For decades, the standard approach to staging prostate cancer has relied on a combination of imaging modalities, including computed tomography (CT) scans, bone scans, and magnetic resonance imaging (MRI). While these methods have been instrumental in guiding treatment decisions, they primarily provide anatomical information, offering a snapshot of the physical structure of organs and tissues. In the context of prostate cancer, conventional imaging excels at detecting larger tumors within the prostate gland and identifying obvious signs of spread to lymph nodes or distant bones. However, these techniques can struggle to detect smaller, more diffuse metastatic deposits that may be present at a molecular or cellular level.
This diagnostic limitation becomes particularly critical in cases of high-risk prostate cancer. These cancers are characterized by aggressive features, such as a high Gleason score (indicating more aggressive cell growth), a large tumor volume, or elevated prostate-specific antigen (PSA) levels. Patients with high-risk disease are at a greater probability of recurrence and spread, even when initial staging suggests localized disease. The challenge lies in accurately identifying the full extent of the cancer to tailor the most effective treatment strategy.
The Dawn of PSMA-PET Imaging in Prostate Cancer
The advent of PSMA-PET imaging represents a paradigm shift in visualizing prostate cancer. Prostate-specific membrane antigen (PSMA) is a protein that is highly expressed on the surface of prostate cancer cells, including those that have metastasized. PSMA-PET utilizes specially designed radioactive tracers, or radiotracers, that bind specifically to PSMA. When injected into the patient, these tracers accumulate in areas where prostate cancer cells are present. A PET scanner then detects the emitted radiation, creating detailed images that highlight the location and extent of the cancer.
Unlike conventional imaging, which offers anatomical detail, PSMA-PET provides functional imaging. It reveals the biological activity of the cancer cells, allowing for the detection of even small clusters of cancerous cells that might be invisible to older technologies. This heightened sensitivity and specificity have made PSMA-PET an increasingly valuable tool in the management of prostate cancer, particularly in detecting recurrent disease and staging aggressive forms of the cancer.
The EMBARK Trial and the Need for Re-evaluation
The current study, conducted by UCLA researchers, was a post hoc analysis of data from patients who were originally enrolled in the EMBARK clinical trial. The EMBARK trial, a pivotal Phase 3 study, investigated the efficacy of adding enzalutamide, a potent androgen deprivation therapy, to standard androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer. The trial demonstrated that this combination significantly improved metastasis-free survival, marking a significant advancement in treatment for this patient population.
However, a key aspect of the EMBARK trial was its reliance on conventional imaging for patient selection and staging. This meant that patients eligible for the trial were classified as having nonmetastatic disease based on the limitations of CT, bone scans, and MRIs. The UCLA study sought to re-evaluate a cohort of patients from the EMBARK trial who were classified as having high-risk, nonmetastatic disease, using the advanced PSMA-PET imaging. The hypothesis was that PSMA-PET might reveal a more extensive disease burden than previously identified.
Unveiling the Hidden Metastases: Study Findings
The retrospective cross-sectional study analyzed data from 182 patients with high-risk recurrent prostate cancer who were considered to have disease confined to the prostate and were eligible for the EMBARK trial based on conventional imaging. When these patients underwent PSMA-PET imaging, the results were striking.
- Significant Detection of Metastases: The study found that PSMA-PET detected cancer metastases in an astonishing 46% of these patients. This means that nearly half of the individuals who were believed to have localized disease were, in fact, experiencing the spread of cancer to distant sites.
- Undetected Lesions: Furthermore, the research highlighted the extent of the underestimation. In 24% of the patients, PSMA-PET identified five or more metastatic lesions that had been entirely missed by conventional imaging. This indicates that for a substantial portion of high-risk patients, the true burden of their disease was significantly greater than initially assessed.
Dr. Adrien Holzgreve, the first author of the study and a visiting assistant professor at the David Geffen School of Medicine at UCLA, expressed his surprise at the high prevalence of metastatic findings. "We anticipated that PSMA-PET would detect more suspicious findings compared to conventional imaging," Dr. Holzgreve stated. "However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases."
Redefining Staging and Treatment Decisions
The implications of these findings are far-reaching, particularly for the clinical management of prostate cancer. Accurate staging is the cornerstone of effective treatment planning. If conventional imaging is systematically underestimating the extent of disease in a significant number of high-risk patients, it raises concerns about the adequacy of initial treatment strategies.
Dr. Jeremie Calais, senior author of the study and director of the Ahmanson Translational Theranostics Division’s clinical research program at UCLA, emphasized the critical role of PSMA-PET. "Our study demonstrates the critical role of PSMA-PET in accurately staging prostate cancer, which can significantly impact treatment decisions and outcomes," Dr. Calais remarked.
In cases where PSMA-PET reveals metastatic disease in patients previously thought to have localized cancer, treatment plans may need to be fundamentally altered. For instance, patients who might have been considered candidates for localized treatments like surgery or radiation therapy might now require systemic therapies such as ADT or chemotherapy. Conversely, the detection of limited metastatic disease might open doors to more targeted approaches, such as SBRT (stereotactic body radiation therapy) or radioligand therapy, which can deliver high doses of radiation directly to cancerous lesions while minimizing damage to surrounding healthy tissues.
Impact on Clinical Trials and Future Research
The study’s findings also cast a new light on the interpretation of results from previous clinical trials, including the EMBARK trial itself. If patient selection for these trials was based on potentially inaccurate staging from conventional imaging, it could influence the generalizability of their findings. This underscores the urgent need to incorporate advanced imaging techniques like PSMA-PET into the design and patient selection criteria for future clinical trials.
"These results challenge the interpretation of previous studies, like the EMBARK trial, and support the inclusion of PSMA-PET for patient selection in clinical and trial interventions in prostate cancer in future major industry-sponsored clinical trials," the study authors concluded. This recommendation aims to ensure that future research accurately reflects the true disease burden of participants, leading to more robust and reliable evidence for treatment efficacy.
Broader Implications and Future Directions
The widespread adoption of PSMA-PET imaging in standard clinical practice could lead to several positive outcomes for prostate cancer patients.
- More Personalized Treatment: By providing a more precise map of the cancer’s spread, PSMA-PET can facilitate truly personalized treatment approaches. This moves away from a one-size-fits-all strategy towards therapies tailored to the individual patient’s disease profile.
- Potential for Earlier Intervention: Identifying metastatic disease earlier could allow for interventions at a stage where treatment is potentially more effective and less aggressive. This could lead to better long-term outcomes and potentially improve cure rates.
- Cost-Effectiveness and Resource Allocation: While advanced imaging can be expensive, a more accurate initial diagnosis could prevent unnecessary or ineffective treatments down the line, potentially leading to better resource allocation and improved patient outcomes in the long run.
However, the integration of new technologies into standard care is a complex process. Challenges include ensuring equitable access to PSMA-PET imaging across different healthcare systems and geographical locations, as well as training healthcare professionals to interpret the scans effectively.
The UCLA team is committed to furthering the understanding of PSMA-PET’s role in prostate cancer management. Ongoing research at UCLA includes analyzing follow-up data from four UCLA trials to assess how PSMA-PET findings influenced treatment decisions and patient outcomes. Furthermore, the team is actively involved in an international consortium studying over 6,000 patients to investigate the prognostic value of PSMA-PET.
"We have good rationales to assume that it is helpful to primarily rely on PSMA-PET findings," Dr. Holzgreve commented. "But more high-quality prospective data would be needed to claim superiority of PSMA-PET for treatment-guidance in terms of patient outcome. However, we are confident PSMA-PET will continue to advance prostate cancer staging and guide personalized therapies."
The study by UCLA researchers serves as a critical wake-up call, highlighting the limitations of current imaging standards and underscoring the transformative potential of PSMA-PET in accurately staging prostate cancer. As this advanced technology becomes more widely available and its clinical utility further validated, it promises to revolutionize how prostate cancer is detected, understood, and treated, ultimately aiming for improved outcomes and a better quality of life for patients.
